Cancer Cachexia and MicroRNAs

Imagem de Miniatura
Arquivos
art_CAMARGO_Cancer_Cachexia_and_MicroRNAs_2015.PDF (1.32 MB)
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA MED ESPORTE
Autores
CAMARGO, Rodolfo Gonzalez
RIBEIRO, Henrique Quintas Teixeira
GERALDO, Murilo Vieira
MATOS-NETO, Emidio
NEVES, Rodrigo Xavier
CARNEVALI JR., Luiz Carlos
DONATTO, Felipe Fedrizzi
SEELAENDER, Marilia
Citação
MEDIATORS OF INFLAMMATION, article ID 367561, 5p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cancer cachexia is a paraneoplastic syndrome compromising quality of life and survival, mainly characterized by involuntary weight loss, fatigue, and systemic inflammation. The syndrome is described as a result of tumor-host interactions characterized by an inflammatory response by the host to the presence of the tumor. Indeed, systemic inflammation is considered a pivotal feature in cachexia progression and maintenance. Cytokines are intimately related to chronic systemic inflammation and the mechanisms underlying the release of these factors are not totally elucidated, the etiology of cachexia being still not fully understood. Therefore, the understanding of cachexia-related mechanisms, as well as the establishment of markers for the syndrome, is very relevant. MicroRNAs (miRNAs) are a class of noncoding RNAs interfering with gene regulation. Different miRNA expression profiles are associated with different diseases and inflammatory processes. miRNAs modulate adipose and skeletal muscle tissue metabolism in cancer cachexia and also tumor and tissue derived inflammation. Therefore, we propose a possible role for miRNAs in the modulation of the host inflammatory response during cachexia. Moreover, the establishment of a robust body of evidence in regard to miRNAs and the mechanisms underlying cachexia is mandatory, and shall contribute to the improvement of its diagnosis and treatment.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/15979
Referências
  1. Agustsson T, 2012, NUTRITION, V28, P851, DOI 10.1016/j.nut.2011.11.026
  2. Argiles JM, 2003, DRUG DISCOV TODAY, V8, P838, DOI 10.1016/S1359-6446(03)02826-5
  3. Argiles JM, 1997, MED RES REV, V17, P477, DOI 10.1002/(SICI)1098-1128(199709)17:5<477::AID-MED3>3.0.CO;2-R
  4. Argiles JM, 2006, CANC TREAT, V130, P199
  5. Argiles JM, 2011, J CACHEXIA SARCOPENI, V2, P87, DOI 10.1007/s13539-011-0027-5
  6. Baldwin Christine, 2011, Curr Opin Support Palliat Care, V5, P29, DOI 10.1097/SPC.0b013e328343a05d
  7. Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577
  8. Batista ML, 2013, CYTOKINE, V61, P532, DOI 10.1016/j.cyto.2012.10.023
  9. Bilir C., 2015, MED ONCOL, V32, P497
  10. Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x
  11. Carta A, 2014, GENETICS RES INT, V2014
  12. Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
  13. COSTA G, 1977, CANCER RES, V37, P2327
  14. Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013
  15. Fearon KCH, 2002, INT J CARDIOL, V85, P73, DOI 10.1016/S0167-5273(02)00235-8
  16. Fearon K, 2011, LANCET ONCOL, V12, P489, DOI [10.1016/S1470-2045(10)70218-7, 10.1016/51470-2045(10)70218-7]
  17. Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
  18. Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
  19. Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043
  20. He WA, 2014, P NATL ACAD SCI USA, V111, P4525, DOI 10.1073/pnas.1402714111
  21. Hilton C, 2013, INT J OBESITY, V37, P325, DOI 10.1038/ijo.2012.59
  22. Hitachi K, 2014, INT J BIOCHEM CELL B, V47, P93, DOI 10.1016/j.biocel.2013.12.003
  23. KATZ AM, 1962, BRIT HEART J, V24, P257
  24. Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006
  25. Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
  26. Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
  27. Kulyte A, 2014, AM J PHYSIOL-ENDOC M, V306, pE267, DOI 10.1152/ajpendo.00249.2013
  28. Lewis A, 2005, CURR BIOL, V15, pR291, DOI 10.1016/j.cub.2005.04.003
  29. MacDonagh L, 2015, CANCER TREAT REV, V41, P160, DOI 10.1016/j.ctrv.2014.12.009
  30. McMillan DC, 2008, P NUTR SOC, V67, P257, DOI 10.1017/S0029665108007131
  31. Muliawati Yanti, 2012, Acta Med Indones, V44, P154
  32. O'Connell RM, 2012, BLOOD, V119, P3875, DOI 10.1182/blood-2012-02-410977
  33. O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957
  34. Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
  35. Reed SA, 2012, FASEB J, V26, P987, DOI 10.1096/fj.11-189977
  36. Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578
  37. Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
  38. Soares RJ, 2014, J BIOL CHEM, V289, P21909, DOI 10.1074/jbc.M114.561845
  39. Suh SY, 2013, SUPPORT CARE CANCER, V21, P3071, DOI 10.1007/s00520-013-1878-4
  40. Tazaki E, 2011, EXP THER MED, V2, P887, DOI 10.3892/etm.2011.286
  41. Thoresen L, 2013, CLIN NUTR, V32, P65, DOI 10.1016/j.clnu.2012.05.009
  42. Tisdale Michael J, 2003, J Support Oncol, V1, P159
  43. Tisdale MJ, 2010, CURR OPIN GASTROEN, V26, P146, DOI 10.1097/MOG.0b013e3283347e77
  44. Wallengren O, 2013, SUPPORT CARE CANCER, V21, P1569, DOI 10.1007/s00520-012-1697-z
  45. Wang JJ, 2014, RNA BIOL, V11, P339, DOI 10.4161/rna.28300
  46. Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08-1299
  47. Xu J, 2012, KIDNEY INT, V82, P401, DOI 10.1038/ki.2012.84
  48. Yin Y, 2012, INT J MOL SCI, V13, P12544, DOI 10.3390/ijms131012544

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - ODS/03